Full-Time

Director Field Technology

CRM

Vertex Pharmaceuticals

Vertex Pharmaceuticals

5,001-10,000 employees

Develops therapies for serious genetic diseases

Compensation Overview

$185.9k - $278.9k/yr

+ Annual bonus + Annual equity awards

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid

Hybrid: work remotely up to two days per week, or work on-site five days per week.

Category
Data & Analytics (1)
Required Skills
CRM

Get referred to Vertex Pharmaceuticals

See people who can refer or advise you

Requirements
  • Deep experience implementing and running technology adoption and optimization across commercial systems, specifically for customer relationship management.
  • Experience managing vendors, contingent workers, and budgets.
  • Deep knowledge of business processes and operations within a commercial biopharmaceutical environment.
  • Exceptional stakeholder management, communication, problem-solving, and presentation skills.
  • A strategic, enterprise mindset with the ability to discern priorities and guide teams with operational excellence.
  • Ability to work independently and navigate ambiguity at a rapid pace across various levels of an organization.
  • At least 15 years of experience in life sciences.
  • At least 8 years of direct experience managing Veeva customer relationship management and directly supporting field teams.
  • At least 8 years of technology-related project management experience.
  • At least 5 years of experience managing a team of at least three direct reports.
Responsibilities
  • Set the strategy and lead execution for customer relationship management and United States commercial field technology enablement.
  • Ensure commercial field teams are equipped with effective, scalable technology that drives engagement, productivity, and decision-making.
  • Shape and operate integrated technology and data solutions for the field, connecting business needs with customer relationship management capabilities, processes, and governance.
  • Partner with business units, leadership teams, Information Technology, Insights and Analytics, and IC and Sales Planning to lead customer relationship management initiatives, innovation, processes, and new ways of working.
  • Advise and guide on best-in-class customer relationship management models, processes, capabilities, and strategic optimization.
  • Collaborate as a customer relationship management subject matter expert with business unit leadership, peers, and their teams to ensure the system supports unique business needs and delivers business value.
  • Bring advanced customer relationship management capabilities, including intelligent and agentic customer relationship management opportunities, to enhance commercialization excellence.
  • Define and lead a comprehensive United States commercial customer relationship management strategy and roadmap supporting enterprise strategy, business objectives, data strategy, and enhanced customer engagement.
  • Develop and implement a prioritization model for customer relationship management initiatives across business units to support resource allocation, defect-free execution, and rapid time to value.
  • Oversee the end-to-end customer relationship management lifecycle and activate fit-for-purpose capabilities for field engagement, task management, target management, and integrations.
  • Oversee the United States commercial customer relationship management migration in collaboration with Information Technology, including planning, execution, and change management.
  • Implement and enforce project management standards for the customer relationship management field technology team.
  • Ensure customer relationship management functionality is aligned with business unit goals across sales and marketing.
  • Collaborate with field operations, sales planning, field analytics, Sales, and Marketing to integrate customer relationship management strategies across departments.
  • Oversee customer relationship management support for IC and sales planning processes, field analytics, sampling, spend transparency, and consent management.
  • Represent the value of the customer relationship management system to leadership teams and govern the process for resolving stakeholder concerns with strategic, permanent, and scalable solutions.
  • Establish standard operating procedures and structured team processes for execution, user support, and operational excellence.
  • Lead and develop a high-performing customer relationship management field technology team.
  • Guide team prioritization, resource allocation, roles and responsibilities, workload management, mentoring, and team development.
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, with a focus on cystic fibrosis. It conducts extensive research and partners with other biotech firms to discover and develop new therapies, including ex vivo engineered cell treatments. Its products, such as ivacaftor, treat cystic fibrosis and other therapies undergo clinical testing to expand the pipeline. Revenue comes from selling approved drugs and from licensing and collaboration agreements. The company distinguishes itself through deep R&D investment, strategic partnerships, and a global reach aimed at addressing unmet medical needs. The overall goal is to bring effective new drugs to patients worldwide and improve outcomes and quality of life.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Get referred to Vertex Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex raised 2026 revenue guidance to $13.1-$13.2 billion after Q2 growth.
  • Povetacicept has a November 30, 2026 PDUFA date, opening nephrology revenue.
  • JOURNAVX hit $50 million in Q2 2026, while CASGEVY grew 151% year over year.

What critics are saying

  • Sionna axed SION-719 on August 10, 2026, but CF competition keeps advancing.
  • Zimislecel faced a voluntary manufacturing pause in 2026, exposing cell-therapy execution risk.
  • Crinetics adds $8.8 billion integration risk; a failed close leaves Vertex overdependent on CF.

What makes Vertex Pharmaceuticals unique

  • Vertex still owns CFTR modulators; Q2 2026 CF revenue reached $3.2 billion.
  • Vertex broadened beyond CF with CASGEVY, JOURNAVX, and Crinetics, announced July 2026.
  • Vertex moves fast: CASGEVY pediatric FDA approval arrived 53 days after filing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

8%

2 year growth

8%
Ticker Report
Aug 19th, 2026
Wealthfront Advisers LLC Makes New $20.67 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX

Wealthfront Advisers LLC acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 41,608 shares of the pharmaceutical company’s stock, valued at approximately $20,668,000. Other hedge funds also recently […]

Yahoo Finance
Aug 14th, 2026
Vertex Pharmaceuticals hits all-time high despite CF competition risks

Vertex Pharmaceuticals recently hit an all-time high after bouncing back from recent setbacks. The biotech continues dominating the cystic fibrosis (CF) market with no meaningful competition, generating $3.2 billion in CF revenue last quarter. Second-quarter sales reached $3.33 billion, up 12% year-over-year, whilst earnings per share rose 8% to $4.31. Several competitors have attempted to challenge Vertex's CF dominance, but most have failed. Sionna Therapeutics' leading CF candidate recently flopped in mid-stage trials, whilst AbbVie previously abandoned its CF programmes. Beyond CF, Vertex is expanding into new areas. The company expects $500 million in non-CF revenue by 2026. Its gene editing treatment Casgevy recently earned approval for children as young as two, whilst non-opioid pain medicine Journavx could gain additional indications.

Yahoo Finance
Aug 12th, 2026
Vertex Pharmaceuticals beats Q2 revenue estimates with $3.33B, driven by CF portfolio and newer products

Vertex Pharmaceuticals reported strong second-quarter results, with revenue of $3.33 billion beating analyst estimates of $3.19 billion. The company attributed growth to its cystic fibrosis portfolio and newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani highlighted that ALYFTREK and TRIKAFTA continued to drive CF revenue, whilst European launches benefitted from fewer monitoring requirements. The company raised its full-year revenue guidance to $13.15 billion at the midpoint from $13.03 billion. Adjusted earnings per share came in at $4.73, in line with analyst expectations of $4.75. Adjusted operating income reached $1.42 billion, exceeding estimates of $1.37 billion with a 42.7% margin. During the earnings call, analysts questioned management about Phase II/III study doses, payer dynamics for JOURNAVX, and clinical outcomes for next-generation CF therapies.

Yahoo Finance
Aug 11th, 2026
Vertex Q2 2026 revenue up 12% year-on-year, announces Crinetics acquisition

Vertex Pharmaceuticals reported strong second quarter 2026 results during its earnings call on 3 August. The company's total revenue grew 12% year-on-year, driven by its cystic fibrosis portfolio and newer products CASGEVY and JOURNAVX. CEO Dr Reshma Kewalramani highlighted excellent performance across the company's commercial portfolio and research pipeline. Vertex also announced a definitive agreement to acquire Crinetics Pharmaceuticals, which will add rare endocrine diseases as a fifth therapeutic area alongside cystic fibrosis, sickle cell disease, beta-thalassemia, and pain management. The company emphasised 2026 as a year focused on execution across commercial, clinical, and regulatory fronts, with significant progress made during the quarter.

Yahoo Finance
Aug 7th, 2026
Sionna Therapeutics challenges Vertex Pharmaceuticals' $12B cystic fibrosis market dominance

Sionna Therapeutics is challenging Vertex Pharmaceuticals' dominance in the cystic fibrosis (CF) drug market. Vertex, valued at nearly $123 billion, generated $3.2 billion in CF-related sales in Q2, representing most of its $3.33 billion total revenue. Sionna, worth $2.2 billion, claims its approach could restore normal function to the CFTR protein, which causes CF when misfolded. Vertex's current treatments improve the protein's shape and function but don't restore normal function for most patients. Vertex generates over $12 billion annually from CF treatments. However, several companies, including AbbVie, have previously attempted to challenge Vertex's market position without success. Vertex has maintained its position since receiving its first CF drug approval in 2012.